ESC 22: The EMPEROR-POOLED Trial: Clinical Benefits of SGLT2i in Heart Failure

Published: 29 Aug 2022

  • Views:

    Views Icon 464
  • Likes:

    Heart Icon 1
Average (ratings)
No ratings
Your rating

ESC Congress 22 — Dr Faiez Zannad (University of Lorraine, FR) joins us onsite at ESC to provide an update on the EMPEROR-Pooled trial, a pooled analysis of the EMPEROR-Preserved and EMPEROR-Reduced studies which aimed to evaluate the effects of empagliflozin on patients with heart failure.

9718 patients with heart failure were pooled into the study, where it was found that the use of empagliflozin reduced the risk of hospitalisation in both trials. 

Recorded onsite at ESC Congress 22, Barcelona.
Interviewer: Mirjam Boros
Editor: Jordan Rance